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Submitted Aug 2, 2013; accepted Nov 13, 2013.DISCUSSIONDr Albeir Mousa (Charleston, WVa). I have two questions.
The ﬁrst, what size perforator you have treated, and how far
from the ulcer location that can still contribute ulcer pathology?
Dr Ellen Dillavou. We follow the Society for Vascular Sur-
gery (SVS) guidelines for pathologic perforators; so, a perforator
of $3.5 mm is considered pathologic and so we will inject any-
thing of that size or larger.
Dr Mousa. So about two-thirds of your cohort was resistant
to treatment. And I notice you keep following them. Did you eval-
uate the central venous system, iliac vein, like any venous outﬂow
study to delineate this issue?
Dr Dillavou. Yes, we perform complete duplexes of all of our
patients initially and then as clinically indicated. So, if we per-
formed our intervention and the ulcer heals, we continue thatcourse. However, if there is a stagnation in healing, we go back
and perform a new duplex ultrasound. If there is any suggestion
of venous outﬂow obstruction, such as with chronic DVT or
dampened femoral waveforms on ultrasound, we would then
perform a central venous study.
Dr Nicos Labropoulos (Stony Brook, NY). That was a great
talk. I think this is real-world data, and this is what you expect
to see in the population you are presenting. However, it is a bit
misleading to indicate that the treatment of the perforators by
the foam is what is causing the ulcers to heal. I believe that the
foam does the job by closing all the reﬂuxing tributaries and partic-
ularly the microvascular tree, which is actually responsible for the
development of the ulcer. And in your population in particular it
is evident, because only one-third of your patients had deep vein
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because you were able to treat a signiﬁcant number of veins within
and around the ulcer.
Dr Dillavou. I completely agree, and one advantage of foam
is that it does treat the network of varicosities. I think this is one
tool. Dr Lawrence has elegantly demonstrated that ablation of per-
forators also increases ulcer healing, so the foam perforator abla-
tion has value. This is just one part of the ulcer treatment package.
Dr Kathleen Gibson (Bellevue, Wash). The question I had,
and I might have missed in your talk, what was your compression
regimen after treatment? Did you track patient compliance? And if
so, did that have any effect on either ulcer healing or the success of
thrombosis of the perforator, or do you think that that is an impor-
tant piece in the healing and in the success of your procedure?
Dr Dillavou. Our standard regimen is to put patients in a
compressive stretch wrap for 24 hours after foam sclerotherapy.
Or if they are in an Unna boot, we put the Unna boot on imme-
diately after the treatment and leave that on for 3 days, or a week,
however long the patient leaves the Unna boot on.
I do think it is important, and in general our patient popula-
tion was very compliant with compression. Unfortunately, the
largely retrospective nature of this study didn’t allow us to control
for each type of compression, and there was a lot of bouncing back
and forth with patients between different types of Unna boots and
short stretch bandages, et cetera. But they were all in high-grade
compression. We are very aggressive with that and, by and large,
the patients are compliant.
Dr Gregory Moneta (Portland, Ore). I have a question about
the status of the patients prior to when you began treating them.
You said that they were all under maximum medical management.
Were these patients de novo patients when they presented to you?
If not, and if they were under your continuous management, why
do you wait 2 years to treat them?
Dr Dillavou.We get a large number of patients referred from
other institutions. And the reason it was only 2 years of compres-
sive therapy prior to intervention for many patients is because
although they would report a history of many years of ulcer,they were not under our care at that time. And so we started
tracking the study from when we knew they were getting adequate
compression and medical therapy. Much of the medical and
compressive therapy was done in our clinics.
This study also reﬂects a change in our practice patterns:
becoming more aggressive with elimination of reﬂuxing perfora-
tors and correction of outﬂow obstruction, and that has happened
over the last few years. Prior to the mid-2000s we were less aggres-
sive in our practice and had a large number of patients who were
treated with compression only.
Dr Alan Dietzek (Danbury, Conn). I was curious, how did
you select your sclerosant regimen for these patients? Do you
use a higher concentration if you don’t get a thrombosis of the
perforator the ﬁrst time? Did you see a difference when you
switched to polidocanol from Sotradecol (AngioDynamics,
Latham, NY)? And have you considered the combined use of
foam sclerotherapy and heat ablation for those perforators that
don’t thrombose with sclerotherapy only?
Dr Dillavou. We switched from Sotradecol to polidocanol as
a group. We made a total change in our practice in May 2010
because we felt that polidocanol was safer and better tolerated
than Sotradecol. We did not see a difference in thrombosis rates
or complications between Sotradecol and polidocanol. Initially
we were using 3% polidocanol for all ultrasound-guided perforator
injections because we felt that that would be more effective. But
then after the Varisolve trial (BTG International Inc, West Con-
shohocken, Pa) results showed that there was not a signiﬁcant dif-
ference between 1% and 3%, we then downgraded to 1% and we
have not seen a difference in our thrombosis rates or complica-
tions. And so now 1% polidocanol is the standard that we use.
Based on these results, we have become more aggressive with
heat ablation of perforators. So anyone with a 5-mm perforator,
the obese men on Coumadin (Bristol-Myers Squibb, Princeton,
NJ), and those who fail ultrasound-guided injection, all get a
heat ablation, and those we are doing as a combined heat ablation
and chemical ablation at the same time hopefully through the same
access site.
